This article is more than 5 years old. Information may no longer be current.
Aequus, Medicom join to commercialize products in US
Aequus Pharmaceuticals and Medicom Healthcare have entered into an exclusive agreement to commercialize ophthalmology products in the United States, according to a press release.
The companies will jointly commercialize the U.K.-based Medicom’s range of preservative-free products, prioritizing programs and developing commercialization plans.
Similar to a joint venture, revenues will be shared equally, with investments and contributions made by each party reconciled through a joint profit and loss statement, the release said.
“The science is clear that non-preserved eye medicines are more beneficial than preserved, and our rich portfolio will benefit U.S. patients as we commercialize products with Aequus,” Medicom founder and CEO Simon Martin said in the release.
“This agreement is highly intuitive for both organizations,” Ian Ball, chief commercial officer of Aequus Pharmaceuticals, added. “Medicom has the fastest growing dry eye portfolio in the U.K., and Aequus is looking forward to launching Medicom’s Evolve line of dry eye disease products in Canada in 2020. Aequus has grown to over 8% market share in our core glaucoma market in Canada, and we believe taking these assets into existing multibillion dollar markets really leverages our collective expertise and is a very natural progression for us all.”